160 related articles for article (PubMed ID: 27387019)
1. High circulating osteoprotegerin levels are associated with non-zero blood groups.
Nagy EE; Varga-Fekete T; Puskas A; Kelemen P; Brassai Z; Szekeres-Csiki K; Gombos T; Csanyi MC; Harsfalvi J
BMC Cardiovasc Disord; 2016 May; 16(1):106. PubMed ID: 27387019
[TBL] [Abstract][Full Text] [Related]
2. An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasma.
Vinholt PJ; Overgaard M; Diederichsen AC; Mickley H; Poulsen TS; Sand NP; Nybo M; Rasmussen LM
Thromb Res; 2013 May; 131(5):396-400. PubMed ID: 23531238
[TBL] [Abstract][Full Text] [Related]
3. Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects.
Giovannini S; Tinelli G; Biscetti F; Straface G; Angelini F; Pitocco D; Mucci L; Landolfi R; Flex A
Cardiovasc Diabetol; 2017 Aug; 16(1):99. PubMed ID: 28789654
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus.
Demková K; Kozárová M; Malachovská Z; Javorský M; Tkáč I
Vasa; 2018 Feb; 47(2):131-135. PubMed ID: 29313442
[TBL] [Abstract][Full Text] [Related]
5. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes.
Niu Y; Zhang W; Yang Z; Li X; Wen J; Wang S; Zhang H; Wang X; Zhou H; Fang W; Qin L; Su Q
BMC Cardiovasc Disord; 2015 Aug; 15():86. PubMed ID: 26260869
[TBL] [Abstract][Full Text] [Related]
6. Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes.
Esteghamati A; Aflatoonian M; Rad MV; Mazaheri T; Mousavizadeh M; Nakhjavani M; Noshad S
Arch Cardiovasc Dis; 2015; 108(8-9):412-9. PubMed ID: 26184866
[TBL] [Abstract][Full Text] [Related]
7. Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention.
Siller-Matula J; Lang IM; Schoergenhofer C; Roest M; Jilma B
Thromb Haemost; 2017 Aug; 117(9):1730-1738. PubMed ID: 28726980
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis.
Lin WC; Tsai JP; Lai YH; Lin YL; Kuo CH; Wang CH; Hsu BG
Ren Fail; 2020 Nov; 42(1):131-136. PubMed ID: 31950864
[TBL] [Abstract][Full Text] [Related]
9. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.
Poulsen MK; Nybo M; Dahl J; Hosbond S; Poulsen TS; Johansen A; Høilund-Carlsen PF; Beck-Nielsen H; Rasmussen LM; Henriksen JE
Cardiovasc Diabetol; 2011 Aug; 10():76. PubMed ID: 21838881
[TBL] [Abstract][Full Text] [Related]
10. Vascular calcification biomarkers and peripheral arterial disease.
Kapetanios D; Karkos C; Giagtzidis I; Papazoglou K; Kiroplastis K; Spyridis C
Int Angiol; 2016 Oct; 35(5):455-9. PubMed ID: 26044839
[TBL] [Abstract][Full Text] [Related]
11. Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis.
Serdaroğlu Beyazal M; Erdoğan T; Türkyılmaz AK; Devrimsel G; Cüre MC; Beyazal M; Sahin I
Clin Rheumatol; 2016 Sep; 35(9):2235-41. PubMed ID: 26847856
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor.
Zannettino AC; Holding CA; Diamond P; Atkins GJ; Kostakis P; Farrugia A; Gamble J; To LB; Findlay DM; Haynes DR
J Cell Physiol; 2005 Aug; 204(2):714-23. PubMed ID: 15799029
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.
Tousoulis D; Siasos G; Maniatis K; Oikonomou E; Kioufis S; Zaromitidou M; Paraskevopoulos T; Michalea S; Kollia C; Miliou A; Kokkou E; Papavassiliou AG; Stefanadis C
Int J Cardiol; 2013 Sep; 167(5):1924-8. PubMed ID: 22640692
[TBL] [Abstract][Full Text] [Related]
14. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
Klejna K; Naumnik B; Koc-Żórawska E; Myśliwiec M
Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
[TBL] [Abstract][Full Text] [Related]
15. Correlations between Vascular Stiffness Indicators, OPG, and 25-OH Vitamin D3 Status in Heart Failure Patients.
Buleu FN; Luca CT; Tudor A; Badalica-Petrescu M; Caraba A; Pah A; Georgescu D; Christodorescu R; Dragan S
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31242663
[No Abstract] [Full Text] [Related]
16. Serum osteoprotegerin is associated with arterial stiffness assessed according to the cardio-ankle vascular index in hypertensive patients.
Lee CJ; Wang JH; Chen ML; Yang CF; Chen YC; Hsu BG
J Atheroscler Thromb; 2015; 22(3):304-12. PubMed ID: 25318352
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin as a marker of atherosclerosis: a systematic update.
Hosbond SE; Poulsen TS; Diederichsen AC; Nybo M; Rasmussen LM; Mickley H
Scand Cardiovasc J; 2012 Aug; 46(4):203-11. PubMed ID: 22506827
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease.
Ziegler S; Kudlacek S; Luger A; Minar E
Atherosclerosis; 2005 Sep; 182(1):175-80. PubMed ID: 16115489
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2014; 32(5):640-6. PubMed ID: 25190453
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study.
Rutten B; Maseri A; Cianflone D; Laricchia A; Cristell NA; Durante A; Spartera M; Ancona F; Limite L; Hu D; Li H; Uren NG; de Groot PG; Mannucci PM; Roest M
Eur Heart J Acute Cardiovasc Care; 2015 Feb; 4(1):64-74. PubMed ID: 24833640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
